XenoPort Issues Statement

SANTA CLARA, Calif.--(BUSINESS WIRE)--

XenoPort, Inc. XNPT today issued the following statement:

“The XenoPort Board of Directors has received the letter sent today from the Clinton Group. The XenoPort Board and management team appreciate stockholder input regarding the company, and we will continue to review all aspects of the company's business. We remain focused on enhancing stockholder value and welcome stockholder input regarding this objective.”

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets, its first approved product in the United States, and developing a novel fumaric acid ester product candidate, XP23829, as a potential treatment for relapsing-remitting multiple sclerosis and/or psoriasis. REGNITE^® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease.

To learn more about XenoPort, please visit the company Website at www.XenoPort.com.

HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.

XNPT2G